AMSTERDAM, July 9, 2013 /PRNewswire/ -- Comprehensive and relevant chemistry and bioactivity related content reduces research timescales and supports rapid user adoption Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced that Karo Bio, a developer of innovative drugs for large medical needs, has started to use Reaxys® and Reaxys® Medicinal Chemistry. Karo Bio has chosen the solutions to support its chemists in their research and development objectives, ensuring they have quick and easy access to state of the art chemistry information. "Comprehensive content is critical to our chemists and the Reaxys solutions give them more relevant results in a single search than other solutions could offer," said Maria Sjöberg, Chief Scientific Officer at Karo Bio. "Not only do our chemists have access to more data, including biological as well as chemical information, but the content is more applicable to their research. We expect the availability of the Reaxys Medicinal Chemistry information alone will reduce research and development time by approximately 20 percent." Reaxys, with its recent expansion of chemistry data and capabilities now encompassing content of over 16,000 periodicals, is recognized by users as having the deepest and richest fact-base of experimentally measured chemistry data. Reaxys Medicinal Chemistry offers access to data from a vast repository of peer-reviewed journal articles and patents and is interoperable with Reaxys. Adding this content to Karo Bio's information sources means that chemists will have readily available access to relevant information. That, coupled with the flexibility of the search function and the way results are presented, will enable chemists to more quickly identify and prioritize viable compounds, helping reduce the time it takes to bring innovative drugs to market. "Researchers in life sciences face an ever growing challenge in making confident and successful decisions in a changing landscape," said Dr. Juergen Swienty-Busch, Head of Product Management for Reaxys. "Karo Bio has a unique knowledge of nuclear receptors as target proteins for the development of novel pharmaceuticals. We are excited that the Reaxys solutions will play a part in increasing the speed at which these projects to discover innovative compounds come to fruition." Reaxys and Reaxys Medicinal Chemistry are part of Elsevier Life Science Solutions, a suite of interoperable, domain-specific, decision support tools which span the discovery and development workflow; including ScienceDirect, Scopus, TargetInsights, Pathway Studio, PharmaPendium, QUOSA and Embase.